Review the major policies of the pharmaceutical industry in 2020

As of December 10, more than 600 policies related to the pharmaceutical industry have been issued at the national level this year, according to yilian system statistics.
, pharmaceutical policy is the largest, accounting for nearly 50% of the total, followed by medical policy, there is a larger proportion of the epidemic-related, although the proportion of health insurance policy decreased from last year, but the heavy policy is not in the minority.
of the drug regulatory agencies, the Drug Administration, as the main department of pharmaceutical policy issues, ranks first in the number of policy releases in various departments.
the Internet medical epidemic, Internet medical treatment has played an important role in alleviating the pressure of offline consultation and reducing cross-infection.
this special period, more and more people choose online consultation, medicine to home and other services, so that Internet telemedicaning has been unprecedented attention and development.
countries have also issued a number of policies to support this.
in the first half of 2020 alone, 215 Internet hospitals were listed, all of which are bound to bring significant challenges and opportunities to the pharmaceutical industry.
following are Internet-related policies issued throughout 2020.
recommended reading: "Internet plus" health care connected to health insurance, ushering in the largest buyer support! Taking advantage of the trend of prescription outflow, the out-of-hospital terminal deer-by-deer medicine new battlefield National Health Insurance Bureau issued a message, pharmaceutical companies have the latest opportunities! National Health Insurance Bureau: online health insurance payment will give priority to the protection of these needs Health insurance catalog adjustment in recent years, the frequency of adjustment of the medical insurance catalog to normal, the volume of the catalog is gradually increasing.
This round of medical insurance catalog adjustment program, compared with the past in the scope, mode, procedures and other aspects have made great changes: OTC only out: in principle, no new OTC; Expanded to August 17, maximize the scope of inclusion, so that more innovative new drugs with higher clinical value in a timely manner, either negotiate, or bid: the new exclusive varieties into the negotiation process, rather than exclusive drugs into the health insurance needs to go through the access bidding link, enterprises want to access the health insurance catalog brought about by the market increment will face the risk of price reduction; Support for epidemic prevention and control work: the implementation of the national new crown pneumonia diagnosis and treatment program drugs into the scope of adjustment, to help the prevention and control of the epidemic.
In recent years, the adjustment rules of the medical insurance catalogue have highlighted the encouragement of innovation, and it is in the interest of highly recognized, newly listed and clinically valuable drugs to be quickly transferred to the catalogue through negotiations, so that innovative pharmaceuticals and related research and development enterprises can quickly obtain market increments.
most of the innovation drug barriers are high, manufacturers are few, health insurance dividends will gradually be concentrated in a few outstanding research and development capabilities of enterprises.
recommended reading: 2020 health care negotiations trends and speculation 31 clinically in urgent need of drugs, which can enter the health care catalog? With health care negotiations over, are innovative drugs fast on the same price as generics? Madden! Drop! Drop! Drop! The 2020 edition of the health insurance catalog officially announced the health insurance policy in 2020 in addition to the adjustment of the health insurance catalog, health care payment reform work has also made important progress, DRG pilot work started, while the introduction of DIP payment method, the relevant pilot list has been published.
from this volume procurement we can find that "high quality and low price" is the direction of policy guidance.
the new situation, pharmaceutical companies in order to survive and develop, we must break the old concept of sales as king, and gradually to innovation, quality and cost as the core competitiveness of products.
enterprises to do, either to enhance the development capacity of new drugs to have exclusive new drug species, or through production process innovation, effectively improve drug quality and drug efficacy, improve production efficiency, reduce production costs.
only in this way can pharmaceutical companies and their products be the beneficiaries of the policies of the moment and gain greater room for development in the future.
recommended reading: The latest! The standard of health care payments is going to change! 10 questions and answers to learn more about the third batch of volume purchases! DrGs policy, high-value consumables or usher in consistent evaluation! Heavy! DRG has made new progress Medical policy this year graded diagnosis and treatment is still the focus of reform, the medical association and the medical community go hand in hand to jointly promote graded diagnosis and treatment;
recommended reading: the new crown epidemic on the pharmaceutical industry five major impact: health insurance, Traditional Chinese medicine, graded diagnosis and treatment ... After three rounds of collection, multinational pharmaceutical companies will turn their attention to this field! If such drugs are not prescribed as required, the physician will be removed from the prescription right medicine policy